As filed with the Securities and Exchange Commission on April 5, 2006.
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
April 5, 2006 (April 5, 2006)
MEDAREX, INC.
(Exact name of registrant as specified in its charter)
|
New Jersey |
|
0-19312 |
|
22-2822175 |
|
(State of other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
|
of incorporation) |
|
|
|
Identification No.) |
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (609) 430-2880
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On April 5, 2006, Medarex, Inc. released certain information relating to certain of as clinical trials of ipilimumab (also known as MDX-010). A copy of the such information is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
|
|
|
Number |
|
|
|
99.1 |
|
Medarex, Inc. Information relating to certain clinical trials of ipilimumab (also known as MDX-010) Press Release dated April 5, 2006. |
3
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MEDAREX, INC. |
||
|
|
Registrant |
||
|
|
|
|
|
|
Date: April 5, 2006 |
By: |
/s/ W. Bradford Middlekauff |
|
|
|
|
W. Bradford Middlekauff |
|
|
|
|
Senior Vice Presiden, General Counsel and Secretary |
|
4
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
Page |
|
99.1 |
|
Medarex, Inc. Information relating to certain clinical trials of ipilimumab (also known as MDX-010) dated April 5, 2006. |
|
|
5